Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-6250 in Healthy Subjects

Next Previous
Trial Profile

A Phase 1a, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-6250 in Healthy Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABI 6250 (Primary)
  • Indications Hepatitis D
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Assembly Biosciences

Most Recent Events

  • 26 Feb 2025 According to Assembly Biosciences media release, first patient has been dosed in this trial. The company expects to share data from the Phase 1a study in Q3 2025.
  • 07 Feb 2025 Status changed from not yet recruiting to recruiting.
  • 19 Dec 2024 According to Assembly Biosciences media release, the company has received regulatory clearance for a Phase 1a study for ABI-6250.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top